Safety Findings for Axi-Cel in Patients With DLBCL
Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.
Brian T. Hill, MD, PhD, a physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic, discussesthe safety findingsfrom the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.
In addition to the efficacy results that demonstrated a complete remission rate around 40% and an overall response rate even higher, the safety findings are comparable to what has been previously seen. Hill says this is in terms of cytokine release syndrome and encephalopathy.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
